Table 3A.
Oocyte Cryopreservation Outcomes for Individual AYA Transmale Cycles.
| Age Range at gender affirmation (years) | Age Range at cycle start (years) | Pre-consultation gender affirming therapy | AMH (ng/ml) | Protocol | Total gonadotrophin dose (IU) | Duration of stimulation (days) | E2 max (pg/mL) | Trigger | Total oocytes retrieved | MII oocytes frozen | MI oocytes frozen | GV oocytes frozen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 and under | 12 and under | 1.58 | Antagonist | 4050 | 10 | 4212 | 1000U hCG + double GnRH-a, 5000U hCG boost | 13 | 3 | 8 | 1 | |
| Antagonist | 5400 | 13 | 5175 | 10,000U hCG + double GnRH-a | 9 | 6 | 1 | 2 | ||||
| 13-15 | 13-15 | Leuprolide acetate | 1.53 | Antagonist | 3700 | 11 | 4288 | 1000U hCG + double GnRH-a | 26 | 5 | 0 | 20 |
| 13-15 | 13-15 | 3.10 | Antagonist | 1750 | 9 | 3049 | 1000U hCG + single GnRH-a | 15 | 9 | 3 | 2 | |
| 13-15 | 13-15 | 3.26 | Antagonist | 2350 | 9 | 3822 | 1000U hCG + double GnRH-a | 22 | 16 | 1 | 4 | |
| ND | 13-15 | 0.73 | Antagonist | 1850 | 9 | 1059 | 1000U hCG + double GnRH-a | 5 | 5 | 0 | 0 | |
| Antagonist | 2825 | 9 | 3084 | 1000U hCG + double GnRH-a | 15 | 8 | 6 | 1 | ||||
| 13-15 | 13-15 | Oral contraception | 2.70 | Antagonist | 2100 | 9 | 4023 | 1000U hCG + double GnRH-a | 25 | 20 | 0 | 5 |
| 13-15 | 13-15 | 4.64 | Antagonist | 3250 | 13 | 2045 | 1000U hCG + single GnRH-a | 19 | 14 | 2 | 3 | |
| ND | 13-15 | 3.27 | Antagonist | 2775 | 10 | 2344 | 5000U hCG + double GnRH-a | 22 | 15 | 3 | 4 | |
| 13-15 | 16-18 | 9.84 | Antagonist | 825 | 8 | 5040 | 1000U hCG + double GnRH-a | 32 | 18 | 3 | 10 | |
| 13-15 | 16-18 | 3.00 | Antagonist | 1725 | 8 | 2848 | 1000U hCG + double GnRH-a | 26 | 19 | 0 | 6 | |
| 13-15 | 16-18 | Oral contraception | 3.60 | Antagonist | 2400 | 9 | 4393 | 1000U hCG + double GnRH-a | 22 | 18 | 0 | 4 |
| 13-15 | 16-18 | 12.87 | Antagonist | 1925 | 10 | 6091** | 1000U hCG + double GnRH-a | 43 | 14 | 3 | 20 | |
| 13-15 | 16-18 | Oral contraception | 0.44 | Antagonist | 4500 | 11 | 2673 | 1000U hCG + double GnRH-a | 9 | 8 | 1 | 0 |
| ND | 16-18 | 5.93 | Antagonist | 2325 | 12 | 3151 | 10,000U hCG | 21 | 17 | 0 | 0 | |
| ND | 16-18 | 0.59 | Antagonist | 4050 | 10 | 3288 | 1000U hCG + double GnRH-a | 33 | 21 | 8 | 3 | |
| ND | 16-18 | 3.27 | Antagonist | 1750 | 8 | 2864 | 1000U hCG + single GnRH-a | 30 | 26 | 1 | 3 | |
| 13-15 | 16-18 | 5.77 | Antagonist | 8075 | 21 | 943ˆ | – | – | – | – | – | |
| 16-18 | 19 and older | 6.18 | Antagonist | 2550 | 10 | 4007** | 1000U hCG + double GnRH-a | 26 | 23 | 2 | 1 | |
| ND | 19 and older | Testosterone + Leuprolide acetate | ND | Low-dose leuprolide acetate downregulation | 1900 | 11 | 6969** | 10,000U hCG | 59 | 35 | 9 | 0 |
| 19 and older | 19 and older | Testosterone | 7.35 | Antagonist | 2175 | 11 | 2792** | 1000U hCG + double GnRH-a | 20 | 18 | 1 | 1 |
ND, not documented.
AMH, Anti-mullerian hormone.
hCG, human chorionic gonadotropin.
E2, Estradiol level.
Total oocytes, Total oocytes (MII, MI, GV).
MII, Metaphase II oocytes.
MI, Metaphase I oocytes.
GV, Germinal Vesicle oocytes.
GnRH-a, gonadotrophin releasing hormone agonist,
Antagonist, gonadotropin-releasing hormone antagonist protocol.
Low-dose leuprolide acetate downregulation = provera for 10 days, leuprolide acetate 10U starting day 6 of provera reducing to 5U on cycle day 2 with initiating of gonadotrophins.
**Denotes experienced ovarian hyperstimulation syndrome (OHSS).
ˆDenotes canceled cycle.